The Application of HCG in Luteal Support for Frozen Embryo Transfer in Ovulation Cycle of Obese Women
The Application of HCG in the Luteal Support of Frozen Embryo Transfer During Ovulation Cycles in Overweight and Obese Women
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
In ART, due to ovulation induction and the particularity of the population, luteal phase deficiency usually exists, and in clinical practice, luteal phase support is routinely strengthened. Progesterone is commonly used for luteal support in clinical practice. According to the Chinese expert consensus on luteal support, HCG can be used for luteal support in the absence of OHSS. HCG can increase progesterone secretion by endogenous stimulation of luteal function and exogenous addition of HCG to enhance luteal support, thereby increasing progesterone production and maintaining luteal function.
At present, it remains unclear whether HCG can improve pregnancy outcomes. Previous studies have indicated that compared with conventional luteal support, HCG has not significantly improved the pregnancy outcomes of frozen-thawed embryo transfer in ovulation cycles (NC). However, with the development and progress of FET technology, while reducing the impact of the technology on frozen embryos, we once again explored whether adding HCG on the basis of traditional luteal support in NC-FET could improve the pregnancy outcomes of obese or overweight patients, providing a theoretical basis for the clinical application of HCG.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age ≤37 years old ② Prepare the endometrium in the natural cycle/ovulation induction cycle ③ BMI≥24 according to the overweight standard for the Asian population ④ Single blastocyst transfer (including IVF and ICSI-assisted pregnancy) ⑤ At least one frozen blastocyst remaining in the IVF/ICSI cycle with a Gardner morphology score of ≥4BC, and the age of the frozen embryo is D5 or D6
Exclusion Criteria:
There is a history of adenomyosis, hydrosalpinx, intrauterine adhesions or untreated submucosal fibroids of the uterus
Uterine malformations; ③ The endometrial thickness on the conversion day is less than 7mm, or the cycle was cancelled during the endometrial preparation process before frozen embryo transfer due to the endometrium being less than 7mm in the past.
- Have a history of the immune system, such as antiphospholipid syndrome/systemic lupus erythematosus/rheumatism; ⑤ Diabetic patients who have not been controlled by standardized medication; ⑥ Those who have undergone embryo transfer more than or equal to two times without achieving a live birth ⑦ Those whose embryos to be thawed and thawed are from donated or frozen egg sources, or have undergone two freezing operations
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: HCG in the luteal support of frozen embryo transfer during ovulation cycles in overweight women
adding HCG on top of the conventional progesterone luteal support can improve the pregnancy outcomes of obese or overweight patients.
|
The application of HCG（Human Chorionic Gonadotropin） in Luteal Support for frozen embryo transfer in Ovulation Cycle of Obese women: A single-center, open-label, randomized controlled trial study
Andra namn:
|
|
Placebo-jämförare: Overweight women who received regular progesterone supplementation during the ovulation cycle
As the control group, the pregnancy outcomes of overweight and obese women who received regular progesterone supplementation during the ovulation cycle were observed.
|
The application of HCG（Human Chorionic Gonadotropin） in Luteal Support for frozen embryo transfer in Ovulation Cycle of Obese women: A single-center, open-label, randomized controlled trial study
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Live birth
Tidsram: Pregnancy at 28 weeks or more
|
Infants with vital signs who were born after 28 weeks of gestation.
|
Pregnancy at 28 weeks or more
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pregnancy outcome
Tidsram: Check HCG 14 days after embryo transfer
|
Pregnancy outcomes: biochemical pregnancy, clinical pregnancy, ongoing pregnancy, termination of pregnancy, ectopic pregnancy, miscarriage
|
Check HCG 14 days after embryo transfer
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Näringsstörningar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Övernäring
- Kroppsvikt
- Graviditetskomplikationer
- Övervikt
- Fetma
- Patologiska tillstånd, tecken och symtom
- Närings- och metabola sjukdomar
- Tecken och symtom
- Graviditet i fetma
- Hormoner
- Hormoner, hormonsubstitut och hormonantagonister
- Peptidhormoner
- Peptider
- Aminosyror, peptider och proteiner
- Proteiner
- Gonadotropiner
- Placenhormoner
- Graviditetsproteiner
- Koriongonadotropin
Andra studie-ID-nummer
- KYLL202511788
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .